{
    "abstract": " Background: We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRM 197 -conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent). Methods: In this phase II, partially-blind, multicentre study (NCT01204658), healthy infants were randomised (1:1:1:1) to receive 11vPHiD-CV, 12vPHiD-CV, PHiD-CV, or 13-valent CRM 197 -conjugate pneumococcal vaccine (PCV13), at 2, 3, and 4 (primary series), and 12\u201315 months of age (booster dose), co-administered with DTPa-HBV-IPV/Hib. Confirmatory objectives assessed non-inferiority of investigational vaccines to comparators (PHiD-CV for common serotypes; PCV13 for 19A and 6A), in terms of percentage of infants with pneumococcal antibody concentrations \u22650.2 \u03bcg/mL and antibody geometric mean concentrations, post-primary vaccination. Reactogenicity and safety were assessed. Results: 951 children received \u22651 primary dose, 919 a booster dose. Pre-defined immunological non-inferiority criteria were met simultaneously for 9/11 11vPHiD-CV serotypes (all except 23F and 19A) and 10/12 12vPHiD-CV serotypes (all except 19A and 6A); thus, non-inferiority objectives were reached. For each PHiD-CV serotype, percentages of children with antibody concentrations \u22650.2 \u00b5g/mL were \u226596.7% post-primary (except 6B [\u226575.2%] and 23F [\u226581.1%]), and \u226598.1% post-booster vaccination. For each PHiD-CV serotype except serotype 1, \u226581.0% and \u226593.9% of children had opsonophagocytic activity titres \u22658, post-primary and booster vaccination. AEs incidence was similar across all groups. SAEs were reported for 117 children (29 in the 11vPHiD-CV group, 26 in the 12vPHiD-CV group, 38 in the PHiD-CV group and 24 in the PCV13 group); 4 SAEs were considered vaccination-related. No fatal events were recorded. Conclusion: Addition of 19A and 6A CRM 197 -conjugates did not alter immunogenicity of the PHiD-CV conjugates; for both investigational vaccines post-booster immune responses to 10 common serotypes appeared similar to those elicited by PHiD-CV. Safety and reactogenicity profiles of the investigational vaccines were comparable to PHiD-CV. Clinical trial registry: NCT01204658. ",
    "author_highlights": [
        {
            "endOffset": 26314,
            "sentence": "11-/12-valent vaccines include 10 PHiD-CV conjugates + 19A(11v) + 6A(12v) CRM-conjugates.",
            "startOffset": 26225
        },
        {
            "endOffset": 26400,
            "sentence": "11vPHiD-CV and 12vPHiD-CV were administered to infants according to a 3 + 1 schedule.",
            "startOffset": 26315
        },
        {
            "endOffset": 26482,
            "sentence": "Immunogenicity was compared to PHiD-CV (common serotypes) and PCV13 (19A and 6A).",
            "startOffset": 26401
        },
        {
            "endOffset": 26573,
            "sentence": "Post-dose 3 immune responses to investigational vaccines were non-inferior to comparators.",
            "startOffset": 26483
        },
        {
            "endOffset": 26662,
            "sentence": "Safety and reactogenicity profiles of 11v/12vPHiD-CV were comparable to that of PHiD-CV.",
            "startOffset": 26574
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [],
            "firstpage": "129",
            "issn": "00498114",
            "lastpage": "144",
            "pmid": "24340399",
            "pub_year": 2012,
            "title": "Pneumococcal vaccines WHO position paper--2012.",
            "volume": "87"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1586/erv.09.113",
            "firstpage": "1479",
            "issn": "14760584",
            "lastpage": "1500",
            "pmid": "19863240",
            "pub_year": 2009,
            "title": "10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122",
            "volume": "8"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Greg L.",
                    "initial": "G.L.",
                    "last": "Plosker"
                }
            ],
            "doi": "10.1007/s40272-013-0047-z",
            "firstpage": "403",
            "issn": "11745878",
            "lastpage": "423",
            "pmid": "24030738",
            "pub_year": 2013,
            "title": "13-valent pneumococcal conjugate vaccine: A review of its use in infants, children, and adolescents",
            "volume": "15"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Carla Magda Allan S.",
                    "initial": "C.M.A.S.",
                    "last": "Domingues"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Verani"
                },
                {
                    "first": "Ernesto Issac",
                    "initial": "E.I.",
                    "last": "Montenegro Renoiner"
                },
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "de Cunto Brandileone"
                },
                {
                    "first": "Brendan",
                    "initial": "B.",
                    "last": "Flannery"
                },
                {
                    "first": "Lucia Helena",
                    "initial": "L.H.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Jo\u00e3o Barberino",
                    "initial": "J.B.",
                    "last": "Santos"
                },
                {
                    "first": "Jos\u00e9 C\u00e1ssio",
                    "initial": "J.C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Regina Coeli Magalh\u00e3es",
                    "initial": "R.C.M.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Marluce Aparecida Assun\u00e7\u00e3o",
                    "initial": "M.A.A.",
                    "last": "Oliveira"
                },
                {
                    "first": "Tani Maria Schilling",
                    "initial": "T.M.S.",
                    "last": "Ranieri"
                },
                {
                    "first": "Gladys Maria",
                    "initial": "G.M.",
                    "last": "Zubaran"
                },
                {
                    "first": "Ana L\u00eddia Lima",
                    "initial": "A.L.L.",
                    "last": "Solon"
                },
                {
                    "first": "Maria Iracema",
                    "initial": "M.I.",
                    "last": "de Aguiar Patr\u00edcio"
                },
                {
                    "first": "Maria Elisa Paula",
                    "initial": "M.E.P.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "de C\u00e1ssia Vilasboas Silva"
                },
                {
                    "first": "Marlene Sera",
                    "initial": "M.S.",
                    "last": "Wille"
                },
                {
                    "first": "Pilar Gomes",
                    "initial": "P.G.",
                    "last": "Martinez"
                },
                {
                    "first": "Helena Keico",
                    "initial": "H.K.",
                    "last": "Sato"
                },
                {
                    "first": "Maria Cristina Hereny",
                    "initial": "M.C.H.",
                    "last": "Bordim"
                },
                {
                    "first": "Luzia Auxiliadora",
                    "initial": "L.A.",
                    "last": "Careli"
                },
                {
                    "first": "Vera L\u00facia",
                    "initial": "V.L.",
                    "last": "da Gl\u00f3ria Malheiros"
                },
                {
                    "first": "Zenize Rocha",
                    "initial": "Z.R.",
                    "last": "da Silva Costa"
                },
                {
                    "first": "Maria Goretti Varej\u00e3o",
                    "initial": "M.G.V.",
                    "last": "da Silva"
                },
                {
                    "first": "Cleidiane Santos",
                    "initial": "C.S.",
                    "last": "Rodrigues"
                },
                {
                    "first": "Ataiza C\u00e9sar",
                    "initial": "A.C.",
                    "last": "Vieira"
                },
                {
                    "first": "Lucila Tacac\u00f4",
                    "initial": "L.T.",
                    "last": "Watanabe"
                },
                {
                    "first": "Glaucia Gama Rahal",
                    "initial": "G.G.R.",
                    "last": "Aires"
                },
                {
                    "first": "Robmary Matias",
                    "initial": "R.M.",
                    "last": "de Almeida"
                },
                {
                    "first": "Diana Felicia",
                    "initial": "D.F.",
                    "last": "de Ara\u00fajo Margarido"
                },
                {
                    "first": "Ana L\u00facia Stone",
                    "initial": "A.L.S.",
                    "last": "de Souza"
                },
                {
                    "first": "Samanta C.G.",
                    "initial": "S.C.G.",
                    "last": "Almeida"
                },
                {
                    "first": "Angela P.",
                    "initial": "A.P.",
                    "last": "Brand\u00e3o"
                },
                {
                    "first": "Lincoln S.",
                    "initial": "L.S.",
                    "last": "Prado"
                },
                {
                    "first": "Maria Luiza L.S.",
                    "initial": "M.L.L.S.",
                    "last": "Guerra"
                },
                {
                    "first": "Orlando Cesar",
                    "initial": "O.C.",
                    "last": "Mantese"
                },
                {
                    "first": "Eitan",
                    "initial": "E.",
                    "last": "Berezin"
                },
                {
                    "first": "Cicero",
                    "initial": "C.",
                    "last": "Dias"
                },
                {
                    "first": "Cristiana",
                    "initial": "C.",
                    "last": "Nascimento"
                },
                {
                    "first": "Joice",
                    "initial": "J.",
                    "last": "Reis"
                },
                {
                    "first": "Ana Lucia",
                    "initial": "A.L.",
                    "last": "Andrade"
                },
                {
                    "first": "Solange",
                    "initial": "S.",
                    "last": "Andrade"
                },
                {
                    "first": "Flavia",
                    "initial": "F.",
                    "last": "Lobo"
                },
                {
                    "first": "Camile",
                    "initial": "C.",
                    "last": "de Moraes"
                },
                {
                    "first": "Eliane Castro",
                    "initial": "E.C.",
                    "last": "de Barros"
                },
                {
                    "first": "M\u00e1rcia Lopes",
                    "initial": "M.L.",
                    "last": "de Carvalho"
                },
                {
                    "first": "Elias Duarte Gon\u00e7alves",
                    "initial": "E.D.G.",
                    "last": "Correia"
                },
                {
                    "first": "Selma Lina",
                    "initial": "S.L.",
                    "last": "Suzuki"
                }
            ],
            "doi": "10.1016/S2213-2600(14)70060-8",
            "firstpage": "464",
            "issn": "22132600",
            "lastpage": "471",
            "pmid": "24726406",
            "pub_year": 2014,
            "title": "Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: A matched case-control study",
            "volume": "2"
        },
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Lucia Helena",
                    "initial": "L.H.",
                    "last": "De Oliveira"
                },
                {
                    "first": "Luiz Antonio B.",
                    "initial": "L.A.B.",
                    "last": "Camacho"
                },
                {
                    "first": "Evandro S.F.",
                    "initial": "E.S.F.",
                    "last": "Coutinho"
                },
                {
                    "first": "Martha S.",
                    "initial": "M.S.",
                    "last": "Martinez-Silveira"
                },
                {
                    "first": "Ana Flavia",
                    "initial": "A.F.",
                    "last": "Carvalho"
                },
                {
                    "first": "Cuauhtemoc",
                    "initial": "C.",
                    "last": "Ruiz-Matus"
                },
                {
                    "first": "Cristiana M.",
                    "initial": "C.M.",
                    "last": "Toscano"
                }
            ],
            "doi": "10.1371/journal.pone.0166736",
            "issn": "19326203",
            "pmid": "27941979",
            "pub_year": 2016,
            "title": "Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: A systematic review",
            "volume": "11"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Myint",
                    "initial": "M.",
                    "last": "Tin Tin Htar"
                },
                {
                    "first": "Dina",
                    "initial": "D.",
                    "last": "Christopoulou"
                },
                {
                    "first": "Heinz Josef",
                    "initial": "H.J.",
                    "last": "Schmitt"
                }
            ],
            "doi": "10.1186/s12879-015-1147-x",
            "issn": "14712334",
            "pmid": "26468008",
            "pub_year": 2015,
            "title": "Pneumococcal serotype evolution in Western Europe",
            "volume": "15"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "McFetridge"
                },
                {
                    "first": "Ajoke Sobanjo ter",
                    "initial": "A.S.t.",
                    "last": "Meulen"
                },
                {
                    "first": "Steven D.",
                    "initial": "S.D.",
                    "last": "Folkerth"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Hoekstra"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Dallas"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Hoover"
                },
                {
                    "first": "Rocio D.",
                    "initial": "R.D.",
                    "last": "Marchese"
                },
                {
                    "first": "Donna M.",
                    "initial": "D.M.",
                    "last": "Zacholski"
                },
                {
                    "first": "Wendy J.",
                    "initial": "W.J.",
                    "last": "Watson"
                },
                {
                    "first": "Jon E.",
                    "initial": "J.E.",
                    "last": "Stek"
                },
                {
                    "first": "Jonathan S.",
                    "initial": "J.S.",
                    "last": "Hartzel"
                },
                {
                    "first": "Luwy K.",
                    "initial": "L.K.",
                    "last": "Musey"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.04.025",
            "firstpage": "2793",
            "issn": "0264410X",
            "lastpage": "2799",
            "pmid": "25913828",
            "pub_year": 2015,
            "title": "Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults",
            "volume": "33"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Claire Anne",
                    "initial": "C.A.",
                    "last": "Siegrist"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.06.026",
            "firstpage": "5513",
            "issn": "0264410X",
            "lastpage": "5523",
            "pmid": "20600514",
            "pub_year": 2010,
            "title": "Glycoconjugate vaccines and immune interference: A review",
            "volume": "28"
        },
        "b0050": {
            "authors": [
                {
                    "first": "N. F.",
                    "initial": "N.F.",
                    "last": "Concepcion"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                }
            ],
            "doi": "10.1128/CDLI.8.2.266-272.2001",
            "firstpage": "266",
            "issn": "1071412X",
            "lastpage": "272",
            "pmid": "11238206",
            "pub_year": 2001,
            "title": "Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay",
            "volume": "8"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                }
            ],
            "doi": "10.1128/CVI.00289-09",
            "firstpage": "134",
            "issn": "15566811",
            "lastpage": "142",
            "pmid": "19889940",
            "pub_year": 2010,
            "title": "Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines",
            "volume": "17"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Durant"
                },
                {
                    "first": "Dany",
                    "initial": "D.",
                    "last": "De Grave"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.09.029",
            "firstpage": "2518",
            "issn": "0264410X",
            "lastpage": "2527",
            "pmid": "17034907",
            "pub_year": 2007,
            "title": "Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children",
            "volume": "25"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "Hyunju",
                    "initial": "H.",
                    "last": "Lee"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Burton"
                },
                {
                    "first": "Kyung Hyo",
                    "initial": "K.H.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1128/CVI.00344-08",
            "firstpage": "376",
            "issn": "15566811",
            "lastpage": "381",
            "pmid": "19144787",
            "pub_year": 2009,
            "title": "Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A",
            "volume": "16"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Juan C.",
                    "initial": "J.C.",
                    "last": "Tejedor"
                },
                {
                    "first": "Dutlef",
                    "initial": "D.",
                    "last": "Grunert"
                },
                {
                    "first": "Ryszard",
                    "initial": "R.",
                    "last": "Konior"
                },
                {
                    "first": "Jose",
                    "initial": "J.",
                    "last": "Garcia-Sicilia"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Bernard"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f609",
            "firstpage": "S77",
            "issn": "08913668",
            "lastpage": "S88",
            "pmid": "19325450",
            "pub_year": 2009,
            "title": "Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines",
            "volume": "28"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Czajka"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Ars\u00e8ne"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f8ef",
            "firstpage": "S66",
            "issn": "08913668",
            "lastpage": "S76",
            "pmid": "19325449",
            "pub_year": 2009,
            "title": "Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine",
            "volume": "28"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.03.107",
            "firstpage": "2959",
            "issn": "0264410X",
            "lastpage": "2961",
            "pmid": "27083428",
            "pub_year": 2016,
            "title": "Status of research and development of pediatric vaccines for Streptococcus pneumoniae",
            "volume": "34"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Amy Sarah",
                    "initial": "A.S.",
                    "last": "Ginsburg"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Farukh M.",
                    "initial": "F.M.",
                    "last": "Khambaty"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1586/erv.12.5",
            "firstpage": "279",
            "issn": "14760584",
            "lastpage": "285",
            "pmid": "22380821",
            "pub_year": 2012,
            "title": "Issues and challenges in the development of pneumococcal protein vaccines",
            "volume": "11"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Aderonke",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "Martin O.C.",
                    "initial": "M.O.C.",
                    "last": "Ota"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Ezra O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "Yauba",
                    "initial": "Y.",
                    "last": "Saidu"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Patrick K.",
                    "initial": "P.K.",
                    "last": "Owiafe"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Ceesay"
                },
                {
                    "first": "Archibald",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Olumuyiwa",
                    "initial": "O.",
                    "last": "Owolabi"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Isatou",
                    "initial": "I.",
                    "last": "Drammeh"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Devos"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Schoonbroodt"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.071",
            "firstpage": "2531",
            "issn": "0264410X",
            "lastpage": "2542",
            "pmid": "28389097",
            "pub_year": 2017,
            "title": "Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study",
            "volume": "35"
        },
        "b0100": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "M. O.",
                    "initial": "M.O.",
                    "last": "Ota"
                },
                {
                    "first": "E. O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Owiafe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1080/21645515.2015.1111496",
            "firstpage": "393",
            "issn": "21645515",
            "lastpage": "402",
            "pmid": "26618243",
            "pub_year": 2016,
            "title": "Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134\u00a0years: A phase II randomized study",
            "volume": "12"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Pazdiora"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.03.066",
            "firstpage": "3025",
            "issn": "0264410X",
            "lastpage": "3034",
            "pmid": "24699466",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial",
            "volume": "32"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Leszek",
                    "initial": "L.",
                    "last": "Szenborn"
                },
                {
                    "first": "Sven Arne",
                    "initial": "S.A.",
                    "last": "Silfverdal"
                },
                {
                    "first": "Jacek",
                    "initial": "J.",
                    "last": "Wysocki"
                },
                {
                    "first": "Piotr",
                    "initial": "P.",
                    "last": "Albrecht"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Asparuh",
                    "initial": "A.",
                    "last": "Gardev"
                },
                {
                    "first": "Yue",
                    "initial": "Y.",
                    "last": "Song"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.07.008",
            "firstpage": "4603",
            "issn": "0264410X",
            "lastpage": "4611",
            "pmid": "28729019",
            "pub_year": 2017,
            "title": "Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants",
            "volume": "35"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Alari"
                },
                {
                    "first": "H\u00e9l\u00e8ne",
                    "initial": "H.",
                    "last": "Chaussade"
                },
                {
                    "first": "Matthieu",
                    "initial": "M.",
                    "last": "Domenech De Cell\u00e8s"
                },
                {
                    "first": "L\u00e9naig",
                    "initial": "L.",
                    "last": "Le Fouler"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Varon"
                },
                {
                    "first": "Lulla",
                    "initial": "L.",
                    "last": "Opatowski"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Guillemot"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Watier"
                }
            ],
            "doi": "10.1186/s12916-016-0755-7",
            "issn": "17417015",
            "pmid": "27998266",
            "pub_year": 2016,
            "title": "Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: A time series analysis",
            "volume": "14"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Kate Ching Ching",
                    "initial": "K.C.C.",
                    "last": "Chan"
                },
                {
                    "first": "Reema",
                    "initial": "R.",
                    "last": "Subramanian"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Chong"
                },
                {
                    "first": "E. Anthony S.",
                    "initial": "E.A.S.",
                    "last": "Nelson"
                },
                {
                    "first": "Hugh Simon",
                    "initial": "H.S.",
                    "last": "Lam"
                },
                {
                    "first": "Albert Martin",
                    "initial": "A.M.",
                    "last": "Li"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Ip"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.05.047",
            "firstpage": "3867",
            "issn": "0264410X",
            "lastpage": "3874",
            "pmid": "27265449",
            "pub_year": 2016,
            "title": "Pneumococcal carriage in young children after introduction of PCV13 in Hong Kong",
            "volume": "34"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Ravinder",
                    "initial": "R.",
                    "last": "Kaur"
                },
                {
                    "first": "Janet R.",
                    "initial": "J.R.",
                    "last": "Casey"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                }
            ],
            "doi": "10.1097/INF.0000000000001206",
            "firstpage": "901",
            "issn": "08913668",
            "lastpage": "906",
            "pmid": "27420806",
            "pub_year": 2016,
            "title": "Emerging streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006-2015",
            "volume": "35"
        },
        "b0130": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kawaguchiya"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Urushibara"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Aung"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Morimoto"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ito"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kudo"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Sumi"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Kobayashi"
                }
            ],
            "doi": "10.1016/j.nmni.2015.11.001",
            "firstpage": "66",
            "issn": "20522975",
            "lastpage": "72",
            "pub_year": 2016,
            "title": "Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan",
            "volume": "9"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Lindstrand"
                },
                {
                    "first": "Ilias",
                    "initial": "I.",
                    "last": "Galanis"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Darenberg"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Morfeldt"
                },
                {
                    "first": "Pontus",
                    "initial": "P.",
                    "last": "Naucler"
                },
                {
                    "first": "Margareta",
                    "initial": "M.",
                    "last": "Blennow"
                },
                {
                    "first": "Tobias",
                    "initial": "T.",
                    "last": "Alfv\u00e9n"
                },
                {
                    "first": "Birgitta",
                    "initial": "B.",
                    "last": "Henriques-Normark"
                },
                {
                    "first": "\u00c5ke",
                    "initial": "\u00c5.",
                    "last": "\u00d6rtqvist"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.07.031",
            "firstpage": "4565",
            "issn": "0264410X",
            "lastpage": "4571",
            "pmid": "27473304",
            "pub_year": 2016,
            "title": "Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden",
            "volume": "34"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Chritina",
                    "initial": "C.",
                    "last": "Bareja"
                },
                {
                    "first": "Cindy",
                    "initial": "C.",
                    "last": "Toms"
                },
                {
                    "first": "Kerryn",
                    "initial": "K.",
                    "last": "Lodo"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "de Kluyver"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "firstpage": "E265",
            "issn": "14474514",
            "lastpage": "E279",
            "pmid": "26234260",
            "pub_year": 2015,
            "title": "Invasive pneumococcal disease in Australia, 2009 and 2010",
            "volume": "39"
        },
        "b0145": {
            "authors": [
                {
                    "first": "James D.",
                    "initial": "J.D.",
                    "last": "Chalmers"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Campling"
                },
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Dicker"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Woodhead"
                },
                {
                    "first": "Harish",
                    "initial": "H.",
                    "last": "Madhava"
                }
            ],
            "doi": "10.1186/s12890-016-0242-0",
            "issn": "14712466",
            "pmid": "27169895",
            "pub_year": 2016,
            "title": "A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults",
            "volume": "16"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Im\u00f6hl"
                },
                {
                    "first": "Jens",
                    "initial": "J.",
                    "last": "M\u00f6ller"
                },
                {
                    "first": "Jens",
                    "initial": "J.",
                    "last": "M\u00f6ller"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Perniciaro"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "van der Linden"
                },
                {
                    "first": "Orhan",
                    "initial": "O.",
                    "last": "Aktas"
                }
            ],
            "doi": "10.1186/s12879-015-0787-1",
            "issn": "14712334",
            "pmid": "25885764",
            "pub_year": 2015,
            "title": "Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: Results of 20 years of nationwide surveillance in Germany",
            "volume": "15"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Van Der Linden"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Falkenhorst"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Perniciaro"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Im\u00f6hl"
                }
            ],
            "doi": "10.1371/journal.pone.0131494",
            "issn": "19326203",
            "pmid": "26132078",
            "pub_year": 2015,
            "title": "Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in germany",
            "volume": "10"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Dagan"
                }
            ],
            "doi": "10.1111/j.1469-0691.2009.02726.x",
            "firstpage": "16",
            "issn": "1198743X",
            "lastpage": "20",
            "pmid": "19366365",
            "pub_year": 2009,
            "title": "Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae",
            "volume": "15"
        },
        "b0165": {
            "authors": [
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hausdorff"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hanage"
                }
            ],
            "doi": "10.1080/21645515.2015.1118593",
            "firstpage": "358",
            "issn": "21645515",
            "lastpage": "374",
            "pmid": "26905681",
            "pub_year": 2016,
            "title": "Interim results of an ecological experiment \u2014 Conjugate vaccination against the pneumococcus and serotype replacement",
            "volume": "12"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Leszek",
                    "initial": "L.",
                    "last": "Szenborn"
                },
                {
                    "first": "Masnuel",
                    "initial": "M.",
                    "last": "Moro"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Petit"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Bermal"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Bernard"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f61b",
            "firstpage": "S97",
            "issn": "08913668",
            "lastpage": "S108",
            "pmid": "19325452",
            "pub_year": 2009,
            "title": "Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV)",
            "volume": "28"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Menno R.",
                    "initial": "M.R.",
                    "last": "Van Den Bergh"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Spijkerman"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Fran\u00e7ois"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Swinnen"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Reinier H.",
                    "initial": "R.H.",
                    "last": "Veenhoven"
                },
                {
                    "first": "Elisabeth A.M.",
                    "initial": "E.A.M.",
                    "last": "Sanders"
                }
            ],
            "doi": "10.1097/INF.0000000000001170",
            "firstpage": "e206",
            "issn": "08913668",
            "lastpage": "e219",
            "pmid": "27097348",
            "pub_year": 2016,
            "title": "Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal Nontypeable H. influenzae Protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children",
            "volume": "35"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Lefebvre"
                },
                {
                    "first": "France",
                    "initial": "F.",
                    "last": "Markowski"
                },
                {
                    "first": "Genevi\u00e8ve",
                    "initial": "G.",
                    "last": "Deceuninck"
                },
                {
                    "first": "Fannie",
                    "initial": "F.",
                    "last": "Defay"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Douville-Fradet"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Landry"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.11.028",
            "firstpage": "1501",
            "issn": "0264410X",
            "lastpage": "1506",
            "pmid": "24486346",
            "pub_year": 2014,
            "title": "Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada",
            "volume": "32"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Jokinen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Rinta-Kokko"
                },
                {
                    "first": "Lotta",
                    "initial": "L.",
                    "last": "Siira"
                },
                {
                    "first": "Arto A.",
                    "initial": "A.A.",
                    "last": "Palmu"
                },
                {
                    "first": "Mikko J.",
                    "initial": "M.J.",
                    "last": "Virtanen"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Anni",
                    "initial": "A.",
                    "last": "Virolainen-Julkunen"
                },
                {
                    "first": "Maija",
                    "initial": "M.",
                    "last": "Toropainen"
                },
                {
                    "first": "J. Pekka",
                    "initial": "J.P.",
                    "last": "Nuorti"
                }
            ],
            "doi": "10.1371/journal.pone.0120290",
            "issn": "19326203",
            "pmid": "25781031",
            "pub_year": 2015,
            "title": "Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children - A population-based study",
            "volume": "10"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jerzy",
                    "initial": "J.",
                    "last": "Brzostek"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Bermal"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Aristegui"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Cleerbout"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f62d",
            "firstpage": "S109",
            "issn": "08913668",
            "lastpage": "S118",
            "pmid": "19325447",
            "pub_year": 2009,
            "title": "Safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines",
            "volume": "28"
        }
    },
    "body_text": [
        {
            "endOffset": 40993,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority of the investigational 11vPHiD-CV was therefore demonstrated.",
            "startOffset": 40916,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 50928,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 50927,
                    "startOffset": 50923
                }
            },
            "secId": "s0070",
            "sentence": "A trend for higher percentages of toddlers with antibody concentrations \u22650.2 \u03bcg/mL and higher antibody GMCs was observed in our study in the 3 PHiD-CV groups compared to a study with a similar target population, in which PHiD-CV was co-administrated with DTPa-HBV-IPV/Hib, according to the same schedule [16].",
            "startOffset": 50619,
            "title": "Discussion"
        },
        {
            "endOffset": 50256,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 50164,
                    "startOffset": 50161
                }
            },
            "secId": "s0070",
            "sentence": "Since immune responses to PHiD-CV for serotype 6B are usually lower than for the other serotypes [2], the difference in carrier might play an important role towards enhancing cross-reactivity.",
            "startOffset": 50064,
            "title": "Discussion"
        },
        {
            "endOffset": 31324,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 31280,
                    "startOffset": 31275
                },
                "b0045": {
                    "endOffset": 31280,
                    "startOffset": 31275
                }
            },
            "secId": "s0005",
            "sentence": "However, adding additional antigens could lead to increased reactogenicity or immunological interference, as previously observed for other vaccines [8,9], and this possibility needs to be assessed.",
            "startOffset": 31127,
            "title": "Introduction"
        },
        {
            "endOffset": 44917,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month post-primary vaccination, for each of the 10 PHiD-CV serotypes except serotype 1, at least 81.0% of infants receiving the investigational vaccines or PHiD-CV had OPA titres \u22658.",
            "startOffset": 44731,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 52676,
            "parents": [],
            "secId": "s0070",
            "sentence": "The results presented here will contribute to further advances in the development of PCVs.",
            "startOffset": 52586,
            "title": "Discussion"
        },
        {
            "endOffset": 46813,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Post-booster vaccination, unsolicited AEs were reported after 29.1\u201333.3% of doses in the 3 PHiD-CV groups (Table 4), with upper respiratory tract infection as the most frequent symptom, following 4.6\u20137.1% of doses in the investigational groups and 5.6\u20139.0% of doses in the comparator groups.",
            "startOffset": 46522,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40059,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The groups were balanced in terms of age and sex distribution; most participants were of White Caucasian heritage (Table S1).",
            "startOffset": 39934,
            "title": "Demographics"
        },
        {
            "endOffset": 50452,
            "parents": [],
            "secId": "s0070",
            "sentence": "We did not make a similar observation for 19A and 19F, also conjugated to different protein carriers (19F to TT and 19A to CRM197), but responses to 19F were in the high ranges for both vaccines.",
            "startOffset": 50257,
            "title": "Discussion"
        },
        {
            "endOffset": 39089,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 39088,
                    "startOffset": 39084
                }
            },
            "secId": "s0035",
            "sentence": "The study power was sufficient to demonstrate non-inferiority for 9/11 (for 11vPHiD-CV) or 10/12 (for 12vPHiD-CV) serotypes, in line with the WHO guidance that meeting non-inferiority criteria for each serotype contained in the candidate vaccine is not an absolute requirement [13].",
            "startOffset": 38807,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38806,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Non-inferiority of 12vPHiD-CV was assessed as a second sequential co-primary objective using the UL of the 2-sided 95.8% CI (1-sided \u03b1 = 2.08%), with the same non-inferiority criteria for at least 10 out of 12 serotypes.",
            "startOffset": 38586,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32967,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Investigational study vaccines are described in Text S2.",
            "startOffset": 32911,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31915,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase II, randomised, partially-blind, multicentre study conducted in Czech Republic, Germany, Poland and Spain, between July 2012 and January 2014.",
            "startOffset": 31756,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33961,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "To comply with the national immunisation schedule, all Spanish children also received a licensed meningococcal serogroup C-tetanus toxoid conjugate vaccine, administered concomitantly with the study vaccine at approximately 2, 4 and 12\u201315 months of age.",
            "startOffset": 33708,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53904,
            "parents": [],
            "secId": "s0075",
            "sentence": "The investigational 11vPHiD-CV and 12vPHiD-CV vaccines given to infants as a 3 + 1 vaccination schedule showed immune responses to the 10 PHiD-CV serotypes which were at least non-inferior to those elicited by the licensed PHiD-CV.",
            "startOffset": 53673,
            "title": "Conclusions"
        },
        {
            "endOffset": 48117,
            "parents": [],
            "secId": "s0070",
            "sentence": "Also, immune responses to 10 serotypes common with PHiD-CV in both investigational vaccines were comparable to those induced by PHiD-CV, in terms of antibody concentrations and their functionality post-primary vaccination.",
            "startOffset": 47895,
            "title": "Discussion"
        },
        {
            "endOffset": 42546,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, 12vPHiD-CV was shown to be non-inferior to comparator vaccines.",
            "startOffset": 42472,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 47894,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 47812,
                    "startOffset": 47808
                }
            },
            "secId": "s0070",
            "sentence": "This study showed that the immune responses induced by the investigational 11vPHiD-CV and 12vPHiD-CV vaccines were non-inferior to the licensed comparator vaccines (PHiD-CV or PCV13) following a 3-dose primary series in infants, by meeting pre-defined serological criteria recommended by the WHO [13] for the vast majority of serotypes (9/11 for 11vPHiD-CV and 10/12 for12vPHiD-CV).",
            "startOffset": 47512,
            "title": "Discussion"
        },
        {
            "endOffset": 40262,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Distribution among groups and reasons for exclusion from the ATP cohorts for immunogenicity are detailed in Fig. 1.",
            "startOffset": 40147,
            "title": "Demographics"
        },
        {
            "endOffset": 42933,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the comparator groups, these percentages were at least 94.5%, except for serotypes 6B and 23F in the PHiD-CV group.",
            "startOffset": 42815,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 43126,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For serotype 19A, antibody concentrations \u22650.2 \u00b5g/mL were observed in at least 95.8% of infants in both investigational groups, and for serotype 6A in 88.3% of infants in the 12vPHiD-CV group.",
            "startOffset": 42934,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 46074,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Grade 3 solicited symptom incidence was below 6.2% post-primary vaccination, and below 8.2% post-booster vaccination in each group (Table 4).",
            "startOffset": 45933,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31013,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 31012,
                    "startOffset": 31009
                }
            },
            "secId": "s0005",
            "sentence": "However, despite their success, the burden of disease caused by serotypes not included in these vaccines remains important [7].",
            "startOffset": 30886,
            "title": "Introduction"
        },
        {
            "endOffset": 35983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 35982,
                    "startOffset": 35978
                }
            },
            "secId": "s0025",
            "sentence": "Pneumococcal serotype-specific immunoglobulin G (IgG) antibodies were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) [10].",
            "startOffset": 35839,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36454,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 36362,
                    "startOffset": 36358
                }
            },
            "secId": "s0025",
            "sentence": "Antibody opsonophagocytic activity (OPA) was measured by a killing-assay [12] and assessed as the percentage of children with titres \u22658 and geometric mean titres (GMTs).",
            "startOffset": 36285,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40146,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The TVC included 951 children for primary vaccination, and 919 for booster vaccination.",
            "startOffset": 40059,
            "title": "Demographics"
        },
        {
            "endOffset": 53471,
            "parents": [],
            "secId": "s0070",
            "sentence": "Potential limitations of the study were the lack of evaluation of T-cell responses and of the immune responses to co-administered vaccines to assess interference with the investigational vaccines.",
            "startOffset": 53275,
            "title": "Discussion"
        },
        {
            "endOffset": 42471,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "The ULs of the 95.8% CIs of the antibody GMC ratios were below the non-inferiority margin for each of the 10 PHiD-CV serotypes, and above it for serotypes 19A and 6A (Fig. 2B, Table S3).",
            "startOffset": 42285,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 37458,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming 85% of enrolled participants would be evaluable, power of the study to demonstrate non-inferiority was 97% for the first confirmatory objective and 90% for the second one (Text S3).",
            "startOffset": 37268,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37267,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A total of 940 infants (235 per group) were to be enrolled.",
            "startOffset": 37208,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 54552,
            "parents": [],
            "secId": "s0080",
            "sentence": "Prevnar 13/Prevenar 13 and NeisVac-C are trademarks of Pfizer Inc.",
            "startOffset": 54486,
            "title": "Trademark statement"
        },
        {
            "endOffset": 47000,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Throughout the study, 154 SAEs were reported in 117 children: 29 children in the 11vPHiD-CV group, 26 in the 12vPHiD-CV group, 38 in the PHiD-CV group and 24 in the PCV13 group (Table 4).",
            "startOffset": 46813,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 50991,
            "parents": [],
            "secId": "s0070",
            "sentence": "Future development of higher-valent PCVs is a challenging task.",
            "startOffset": 50928,
            "title": "Discussion"
        },
        {
            "endOffset": 38042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immunogenicity analyses were performed on the according-to-protocol (ATP) cohorts for immunogenicity for primary or booster vaccination, which included all evaluable study participants (according to the eligibility criteria and compliance with the study procedures) with available assay results for at least 1 study vaccine component.",
            "startOffset": 37708,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 52586,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our study showed that more serotypes can be added to PHiD-CV without impacting the immune response against vaccine serotypes.",
            "startOffset": 52461,
            "title": "Discussion"
        },
        {
            "endOffset": 48762,
            "parents": [],
            "secId": "s0070",
            "sentence": "For serotype 6A, pre-specified non-inferiority criteria were not met for 12vPHiD-CV.",
            "startOffset": 48678,
            "title": "Discussion"
        },
        {
            "endOffset": 52460,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 52322,
                    "startOffset": 52319
                },
                "b0020": {
                    "endOffset": 52459,
                    "startOffset": 52450
                },
                "b0180": {
                    "endOffset": 52459,
                    "startOffset": 52450
                },
                "b0185": {
                    "endOffset": 52459,
                    "startOffset": 52450
                }
            },
            "secId": "s0070",
            "sentence": "PHiD-CV includes 3 distinct proteins as carriers, and its efficacy and effectiveness was demonstrated in clinical [2] and post-marketing studies, with the latter indicating that protection against IPD extends to the vaccine-related serotype 19A [4,36,37].",
            "startOffset": 52205,
            "title": "Discussion"
        },
        {
            "endOffset": 53274,
            "parents": [],
            "secId": "s0070",
            "sentence": "The study\u2019s main strength was its design, with sufficient power to demonstrate the 2 co-primary confirmatory objectives of immunological non-inferiority.",
            "startOffset": 53121,
            "title": "Discussion"
        },
        {
            "endOffset": 41786,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For 10 of the 12vPHiD-CV serotypes (all except 23F and 6A), the UL of the 2-sided 95.8% CI of the difference in the percentage of children with antibody concentrations \u22650.2 \u03bcg/mL between comparator and 12vPHiD-CV vaccines was below 10%.",
            "startOffset": 41550,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 49357,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 49344,
                    "startOffset": 49340
                },
                "b0070": {
                    "endOffset": 49356,
                    "startOffset": 49352
                }
            },
            "secId": "s0070",
            "sentence": "Although neither of the 2 alternative serological non-inferiority criteria recommended by the WHO was met for 6A, the functionality of elicited antibodies as assessed by OPA was previously observed to better reflect effectiveness against IPD than antibody levels for several pneumococcal serotypes, including 6A [12] or 19A [14].",
            "startOffset": 49028,
            "title": "Discussion"
        },
        {
            "endOffset": 51189,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 51150,
                    "startOffset": 51143
                },
                "b0090": {
                    "endOffset": 51150,
                    "startOffset": 51143
                },
                "b0095": {
                    "endOffset": 51188,
                    "startOffset": 51181
                },
                "b0100": {
                    "endOffset": 51188,
                    "startOffset": 51181
                },
                "b0105": {
                    "endOffset": 51188,
                    "startOffset": 51181
                },
                "b0110": {
                    "endOffset": 51188,
                    "startOffset": 51181
                }
            },
            "secId": "s0070",
            "sentence": "Different approaches are being pursued, such as the addition of more serotypes to multivalent PCVs or the development of serotype-independent vaccines [17,18] using well-conserved proteins [19\u201322].",
            "startOffset": 50992,
            "title": "Discussion"
        },
        {
            "endOffset": 38165,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "OPA and protein D analyses were carried out on subsets of approximately 50% of randomly selected children from each group.",
            "startOffset": 38043,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33492,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Investigational study vaccines are described in Text S2.",
            "startOffset": 33436,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.07.023.",
            "startOffset": 32214,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53548,
            "parents": [],
            "secId": "s0070",
            "sentence": "No statistical analyses were carried out to compare the 2 licensed vaccines.",
            "startOffset": 53472,
            "title": "Discussion"
        },
        {
            "endOffset": 39634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The percentages of doses followed by solicited and unsolicited AEs, grade 3 symptoms and AEs with causal relationship to vaccination were tabulated with exact 95% CI for each group.",
            "startOffset": 39453,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 45193,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "OPA results are not currently available for serotype 19A, but will be disclosed at a later time.",
            "startOffset": 45097,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 45294,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Immune responses to protein D appeared similar across the PHiD-CV groups at all timepoints (Table 3).",
            "startOffset": 45193,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 45096,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For serotype 6A, all infants in the 12vPHiD-CV group had OPA titres \u22658 post-booster vaccination (Table 2).",
            "startOffset": 44990,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 45532,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Following primary vaccination, pain at the injection site was the most frequent local symptom, reported after 37.5\u201340.2% of doses in the investigational groups, and after 35.4\u201337.9% of comparator vaccine doses.",
            "startOffset": 45322,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43772,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For serotype 6A, 94.4% and 90.7% of infants in the 12vPHiD-CV and PCV13 groups, respectively, had antibody concentrations \u22650.2 \u00b5g/mL (Table 1).",
            "startOffset": 43629,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 30885,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 30884,
                    "startOffset": 30879
                },
                "b0030": {
                    "endOffset": 30884,
                    "startOffset": 30879
                }
            },
            "secId": "s0005",
            "sentence": "There is growing evidence showing that PHiD-CV and PCV13 have a comparable, significant impact on IPD [5,6].",
            "startOffset": 30777,
            "title": "Introduction"
        },
        {
            "endOffset": 46213,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Six toddlers (3 each in the 12vPHiD-CV and PHiD-CV groups) had large swelling reactions at the injection site of the PCV post-booster dose.",
            "startOffset": 46074,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 34106,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Treatment allocation was performed by a central internet-based randomisation system through a minimisation algorithm accounting for study centre.",
            "startOffset": 33961,
            "title": "Study design and participants"
        },
        {
            "endOffset": 54291,
            "parents": [],
            "secId": "s0075",
            "sentence": "The 6A and 19A conjugates in 11vPHiD-CV and 12vPHiD-CV did not appear to negatively alter the immunogenicity of the 10 conjugates or protein D. Despite non-inferiority criteria not being met for both IgG and functional antibodies for serotypes 19A and 6A, the percentages of children with antibody concentrations over the pre-specified threshold were high following primary vaccination.",
            "startOffset": 53905,
            "title": "Conclusions"
        },
        {
            "endOffset": 46328,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Post-primary vaccination, at least 1 unsolicited AE was reported after 23.4\u201327.2% of doses in each group (Table 4).",
            "startOffset": 46213,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 33707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib, Infanrix hexa, GSK) was co-administered as part of the routine immunisation programme.",
            "startOffset": 33493,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37185,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Serious adverse events (SAEs) were defined as any untoward medical occurrences that resulted in death, were life-threatening, required or prolonged hospitalisation, or resulted in disability or incapacity, and were collected throughout the study.",
            "startOffset": 36939,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43215,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the comparator (PCV13) group, this percentage was 99.5% for both serotypes (Table 1).",
            "startOffset": 43127,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 43628,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For serotype 19A, the percentages of infants with antibody concentrations \u22650.2 \u00b5g/mL were 76.9% and 73.9% in 11vPHiD-CV and 12vPHiD-CV groups respectively, compared to 76.4% in the PCV13 group.",
            "startOffset": 43435,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 48677,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 48676,
                    "startOffset": 48672
                }
            },
            "secId": "s0070",
            "sentence": "Nevertheless, according to the WHO recommendations, meeting 1 of the 2 alternative serological criteria for non-inferiority is considered acceptable, and assessment of pneumococcal vaccines should also be made on a serotype to serotype basis, by taking into account the burden of disease associated with each serotype, together with any available effectiveness data [13].",
            "startOffset": 48306,
            "title": "Discussion"
        },
        {
            "endOffset": 44410,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The ranges were similar across the 3 PHiD-CV groups, except for serotype 6B post-booster dose, for which antibody GMCs were significantly higher in the 12vPHiD-CV group compared with the other 2.",
            "startOffset": 44215,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 30059,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 30058,
                    "startOffset": 30055
                }
            },
            "secId": "s0005",
            "sentence": "Streptococcus pneumoniae is an important cause of childhood diseases, including acute otitis media, pneumonia, non-invasive and invasive pneumococcal disease (IPD), which together account for a large proportion of deaths in children <5 years of age worldwide [1].",
            "startOffset": 29796,
            "title": "Introduction"
        },
        {
            "endOffset": 40748,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-primary vaccination, for the difference between the comparator and 11vPHiD-CV group in the percentage of infants with pneumococcal antibody concentrations \u22650.2 \u03bcg/mL the ULs of the 95.9% CIs were below the non-inferiority margin for each of the 10 PHiD-CV serotypes except 23F (Fig. 2A, Table S2).",
            "startOffset": 40436,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 47275,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Four SAEs were considered by the investigator to be causally related to vaccination: 2 in the 12vPHiD-CV group (pyrexia occurring in 2 different children, 1 day post-dose 1), 1 in the 11vPHiD-CV group (head injury), and 1 in the PHiD-CV group (pyrexia on the day of dose 2).",
            "startOffset": 47001,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36880,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and general symptoms within 4 days post-vaccination (days 0\u20133), and unsolicited adverse events (AEs) within 31 days post-vaccination (days 0\u201330), graded by intensity, were recorded.",
            "startOffset": 36683,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 50063,
            "parents": [],
            "secId": "s0070",
            "sentence": "This may be explained by cross-reacting antibodies against 6A, despite \u2013 or maybe due to \u2013 the 2 capsular polysaccharides being conjugated to different protein carriers (protein D for 6B and CRM197 for 6A).",
            "startOffset": 49857,
            "title": "Discussion"
        },
        {
            "endOffset": 41305,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-primary vaccination, for the difference between the comparator and 11vPHiD-CV group in the percentage of infants with pneumococcal antibody concentrations \u22650.2 \u03bcg/mL the ULs of the 95.9% CIs were below the non-inferiority margin for each of the 10 PHiD-CV serotypes except 23F (Fig. 2A, Table S2).",
            "startOffset": 40993,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 34582,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol, amendments, and informed consent forms were reviewed and approved by national Independent Ethics Committees.",
            "startOffset": 34460,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45675,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Irritability/fussiness was the most frequently reported general symptom, after 53.5% (for PCV13) to 61.7% (for 12vPHiD-CV) of doses (Table 4).",
            "startOffset": 45533,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 47501,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "No fatal events were reported.",
            "startOffset": 47471,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 49027,
            "parents": [],
            "secId": "s0070",
            "sentence": "Moreover, all children vaccinated with 12vPHiD-CV had OPA titres \u22658 post-booster vaccination.",
            "startOffset": 48934,
            "title": "Discussion"
        },
        {
            "endOffset": 40388,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The groups were balanced in terms of age and sex distribution; most participants were of White Caucasian heritage (Table S1).",
            "startOffset": 40263,
            "title": "Demographics"
        },
        {
            "endOffset": 32911,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants were randomised (1:1:1:1) into 4 groups to receive 1 of the 2 investigational vaccines (11vPHiD-CV or 12vPHiD-CV), PHiD-CV, or PCV13, administered at approximately 2, 3, and 4 months (primary series) and 12\u201315 months of age (booster dose) (3 + 1 schedule).",
            "startOffset": 32647,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30606,
            "parents": [],
            "secId": "s0005",
            "sentence": "These PCVs contain 10 and 13 pneumococcal antigens, respectively and additionally offer the potential to protect against vaccine-related serotypes belonging to the same serogroups as those contained in the vaccines.",
            "startOffset": 30391,
            "title": "Introduction"
        },
        {
            "endOffset": 40915,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority criteria in terms of antibody GMC ratios between the comparator and 11vPHiD-CV groups were also met for all serotypes, except 19A (Fig. 2B, Table S3).",
            "startOffset": 40749,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 31716,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study aimed to demonstrate immunological non-inferiority of 11vPHiD-CV and 12vPHiD-CV when compared to the 2 licensed vaccines, 1 month after a 3-dose primary vaccination.",
            "startOffset": 31540,
            "title": "Introduction"
        },
        {
            "endOffset": 41973,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "The ULs of the 95.8% CIs of the antibody GMC ratios were below the non-inferiority margin for each of the 10 PHiD-CV serotypes, and above it for serotypes 19A and 6A (Fig. 2B, Table S3).",
            "startOffset": 41787,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 44731,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Antibody GMCs were considerably higher in the PCV13 than in PHiD-CV groups for serotype 19A post-primary and post-booster vaccination, and for serotype 6A post-primary vaccination, while higher pre-booster values were observed for serotype 6A in the 12vPHiD-CV than in the PCV13 group (non-overlapping 95% CIs; Table 1).",
            "startOffset": 44411,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 51667,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, the prevalence and impact of emerging serotypes vary by region, age, and time after PCV introduction.",
            "startOffset": 51557,
            "title": "Discussion"
        },
        {
            "endOffset": 54485,
            "parents": [],
            "secId": "s0080",
            "sentence": "Synflorix and Infanrix hexa are trademarks of the GSK group of companies.",
            "startOffset": 54412,
            "title": "Trademark statement"
        },
        {
            "endOffset": 43434,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Pre-booster dose, for each of the 10 PHiD-CV serotypes except serotype 1, at least 83.1% of infants in the investigational groups had antibody concentrations \u22650.2 \u00b5g/mL, compared to 86.4% in the PHiD-CV group (Table 1).",
            "startOffset": 43215,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 39226,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All other comparisons were descriptive, and they should be interpreted with caution, since no adjustment for multiplicity was performed.",
            "startOffset": 39090,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44214,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For each of the PHiD-CV serotypes, antibody GMCs increased from pre-vaccination levels post-primary vaccination, decreased pre-booster dose (but remained higher than at baseline), and increased again post-booster vaccination.",
            "startOffset": 43989,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 34459,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 34343,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39452,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety and reactogenicity assessments were carried out on total vaccinated cohorts (TVCs) for primary or booster vaccination, which included all children who received at least 1 primary dose, or the booster dose, respectively.",
            "startOffset": 39226,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41472,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority criteria in terms of antibody GMC ratios between the comparator and 11vPHiD-CV groups were also met for all serotypes, except 19A (Fig. 2B, Table S3).",
            "startOffset": 41306,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 49725,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 49724,
                    "startOffset": 49720
                }
            },
            "secId": "s0070",
            "sentence": "The addition of 19A and 6A serotype-specific CRM197-conjugates to PHiD-CV did not seem to impact negatively the immune responses against the 10 common serotypes; the immune response elicited by 11vPHiD-CV and 12vPHiD-CV appeared similar to that induced by PHiD-CV, and was in line with previous reports on PHiD-CV co-administered with routine paediatric vaccines [15].",
            "startOffset": 49357,
            "title": "Discussion"
        },
        {
            "endOffset": 30777,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 30776,
                    "startOffset": 30773
                }
            },
            "secId": "s0005",
            "sentence": "For example, PHiD-CV was shown to offer protection against disease due to serotype 19A through cross-reactive antibodies elicited by the 19F polysaccharide conjugate [4].",
            "startOffset": 30607,
            "title": "Introduction"
        },
        {
            "endOffset": 33182,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib, Infanrix hexa, GSK) was co-administered as part of the routine immunisation programme.",
            "startOffset": 32968,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy infants 6\u201312 weeks of age who had not been previously vaccinated against S. pneumoniae and did not meet any of the exclusion criteria (Supplementary Material, Text S1) were enrolled in the study, after written informed consent was obtained from parents or legally acceptable representatives.",
            "startOffset": 31915,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35128,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The first co-primary objectives were to demonstrate that 11vPHiD-CV co-administered with DTPa-HBV-IPV/Hib as a 3-dose primary vaccination course is non-inferior for at least 9 out of 11 vaccine pneumococcal serotypes to PHiD-CV (for 10 serotypes) or to PCV13 (for 19A) in terms of percentage of children with antibody concentrations \u22650.2 \u00b5g/mL and antibody geometric mean concentrations (GMCs).",
            "startOffset": 34734,
            "title": "Study objectives"
        },
        {
            "endOffset": 36284,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 36283,
                    "startOffset": 36279
                }
            },
            "secId": "s0025",
            "sentence": "For each group, immune responses to each serotype were expressed as antibody GMCs and the percentage of children with IgG concentrations \u22650.2 \u00b5g/mL, which is equivalent to concentrations of \u22650.35 \u00b5g/mL as measured by the non-22F ELISA of the World Health Organization (WHO) reference laboratory [11].",
            "startOffset": 35984,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 52204,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 52203,
                    "startOffset": 52200
                },
                "b0170": {
                    "endOffset": 52130,
                    "startOffset": 52123
                },
                "b0175": {
                    "endOffset": 52130,
                    "startOffset": 52123
                }
            },
            "secId": "s0070",
            "sentence": "Co-administration of DTPa-HBV-IPV/Hib with PHiD-CV has been shown to increase anti-polyribosylribitol-phosphate antibody GMCs, compared to co-administration with the 7-valent PCV (PCV7) [34,35], probably due to the different nature and dosage of carrier proteins [9].",
            "startOffset": 51937,
            "title": "Discussion"
        },
        {
            "endOffset": 36938,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Large swelling reactions were recorded post-booster dose.",
            "startOffset": 36881,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31126,
            "parents": [],
            "secId": "s0005",
            "sentence": "This could potentially be addressed by adding more polysaccharide conjugates to currently licensed formulations.",
            "startOffset": 31014,
            "title": "Introduction"
        },
        {
            "endOffset": 34715,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at ClinicalTrials.gov (NCT01204658) and available at https://www.gsk-clinicalstudyregister.com/study/116485.",
            "startOffset": 34583,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35838,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples of approximately 3.5 mL (pre-vaccination) or 5 mL (1 month post-primary vaccination, pre- and 1 month post-booster vaccination) were collected and sera were stored at maximum \u221220 \u00b0C.",
            "startOffset": 35642,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36682,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All events were reported by parents or legally acceptable representatives using diary cards.",
            "startOffset": 36590,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 35329,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The second co-primary objectives assessed non-inferiority of 12vPHiD-CV in the same terms, for at least 10 out of 12 pneumococcal serotypes to PHiD-CV (for 10 serotypes) and to PCV13 (for 6A and 19A).",
            "startOffset": 35129,
            "title": "Study objectives"
        },
        {
            "endOffset": 39707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Analyses were performed using SAS in SAS Drug and Development web portal.",
            "startOffset": 39634,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 54392,
            "parents": [],
            "secId": "s0075",
            "sentence": "Both investigational vaccines showed acceptable reactogenicity profiles, similar to that of PHiD-CV.",
            "startOffset": 54292,
            "title": "Conclusions"
        },
        {
            "endOffset": 45770,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The same symptoms were the most frequently reported post-booster dose in all groups (Table 4).",
            "startOffset": 45676,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 51763,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 51762,
                    "startOffset": 51758
                }
            },
            "secId": "s0070",
            "sentence": "This complicates determining which serotypes should be included into a higher-valency PCV [33].",
            "startOffset": 51668,
            "title": "Discussion"
        },
        {
            "endOffset": 39933,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Distribution among groups and reasons for exclusion from the ATP cohorts for immunogenicity are detailed in Fig. 1.",
            "startOffset": 39818,
            "title": "Demographics"
        },
        {
            "endOffset": 46521,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The most frequent unsolicited symptom was upper respiratory tract infection, reported following 6.9\u20137.4% of doses in the investigational groups, and 4.9\u20138.5% of doses in the comparator groups.",
            "startOffset": 46329,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 34343,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in a partially-blinded manner: double-blind for the 3 PHiD-CV groups, but single-blind (investigators were aware of the administered vaccine) for the PCV13 group, due to differences in the vaccines\u2019 presentation.",
            "startOffset": 34107,
            "title": "Study design and participants"
        },
        {
            "endOffset": 49856,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, antibody GMCs for serotype 6B were higher post-booster dose in the 12vPHiD-CV group when compared with the PHiD-CV group.",
            "startOffset": 49726,
            "title": "Discussion"
        },
        {
            "endOffset": 30390,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 30306,
                    "startOffset": 30303
                },
                "b0015": {
                    "endOffset": 30389,
                    "startOffset": 30386
                }
            },
            "secId": "s0005",
            "sentence": "Two pneumococcal conjugate vaccines (PCVs) are currently widely used and have shown effectiveness against various pneumococcal diseases: the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV, Synflorix, GSK) [2] and the 13-valent CRM197-conjugate PCV (PCV13, Prevenar 13/Prevnar 13, Pfizer) [3].",
            "startOffset": 30059,
            "title": "Introduction"
        },
        {
            "endOffset": 52781,
            "parents": [],
            "secId": "s0070",
            "sentence": "Both investigational vaccines showed a reactogenicity profile very similar to that observed for PHiD-CV.",
            "startOffset": 52677,
            "title": "Discussion"
        },
        {
            "endOffset": 42814,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month post-primary vaccination, for each of the 10 PHiD-CV serotypes except 6B and 23F, at least 96.7% of infants in the groups receiving the investigational vaccines had antibody concentrations \u22650.2 \u00b5g/mL.",
            "startOffset": 42604,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 51556,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 51485,
                    "startOffset": 51476
                },
                "b0115": {
                    "endOffset": 51236,
                    "startOffset": 51229
                },
                "b0120": {
                    "endOffset": 51236,
                    "startOffset": 51229
                },
                "b0125": {
                    "endOffset": 51236,
                    "startOffset": 51229
                },
                "b0130": {
                    "endOffset": 51236,
                    "startOffset": 51229
                },
                "b0135": {
                    "endOffset": 51236,
                    "startOffset": 51229
                },
                "b0140": {
                    "endOffset": 51485,
                    "startOffset": 51476
                },
                "b0145": {
                    "endOffset": 51485,
                    "startOffset": 51476
                },
                "b0150": {
                    "endOffset": 51485,
                    "startOffset": 51476
                },
                "b0155": {
                    "endOffset": 51485,
                    "startOffset": 51476
                },
                "b0160": {
                    "endOffset": 51555,
                    "startOffset": 51551
                }
            },
            "secId": "s0070",
            "sentence": "The emergence of non-vaccine serotypes [23\u201327] may be addressed by the addition of new serotypes in the vaccine composition, as done for the 2 investigational formulations containing serotypes 19A and 6A (for 12vPHiD-CV), especially since serotype 19A remains an important cause of IPD [7,28\u201331] and its multi-drug resistance makes it more difficult to control [32].",
            "startOffset": 51190,
            "title": "Discussion"
        },
        {
            "endOffset": 39817,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The TVC included 951 children for primary vaccination, and 919 for booster vaccination.",
            "startOffset": 39730,
            "title": "Demographics"
        },
        {
            "endOffset": 45932,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Slightly higher incidences of injection site pain post-booster dose (after 47.6\u201354.9% of doses in all groups) compared to post-primary vaccination were observed.",
            "startOffset": 45771,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 51936,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 51935,
                    "startOffset": 51932
                }
            },
            "secId": "s0070",
            "sentence": "The polysaccharide/carrier ratio in PCVs is also important and it has been discussed to impact the immune response to pneumococcal antigens and co-administered vaccines [9].",
            "startOffset": 51763,
            "title": "Discussion"
        },
        {
            "endOffset": 41550,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority of the investigational 11vPHiD-CV was therefore demonstrated.",
            "startOffset": 41473,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 42048,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, 12vPHiD-CV was shown to be non-inferior to comparator vaccines.",
            "startOffset": 41974,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 42284,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For 10 of the 12vPHiD-CV serotypes (all except 23F and 6A), the UL of the 2-sided 95.8% CI of the difference in the percentage of children with antibody concentrations \u22650.2 \u03bcg/mL between comparator and 12vPHiD-CV vaccines was below 10%.",
            "startOffset": 42048,
            "title": "Non-inferiority assessment"
        },
        {
            "endOffset": 47470,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "All reported SAEs were resolved by study end except for 3: retinoblastoma in the 11vPHiD-CV group, hypotonia in the PHiD-CV group, and pneumonia in the 12vPHiD-CV group (resolved with sequelae).",
            "startOffset": 47276,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 35625,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives included assessing the immune response to pneumococcal serotype-specific polysaccharides and to protein D post-primary and post-booster vaccination, antibody persistence 8\u201311 months after the last primary dose, and safety and reactogenicity of the 2 investigational vaccines.",
            "startOffset": 35329,
            "title": "Study objectives"
        },
        {
            "endOffset": 48933,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, following primary vaccination, at least 96% of children had OPA titres \u22658 against serotype 6A in the groups receiving 12vPHiD-CV and PCV13 (overlapping 95% CIs).",
            "startOffset": 48763,
            "title": "Discussion"
        },
        {
            "endOffset": 53121,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 53031,
                    "startOffset": 53028
                },
                "b0045": {
                    "endOffset": 53120,
                    "startOffset": 53117
                }
            },
            "secId": "s0070",
            "sentence": "However, adding more serotypes may also trigger an increase in reactogenicity, as previously shown for a 15-valent PCV [8], and a potential interference with the immune responses to other paediatric vaccines [9].",
            "startOffset": 52909,
            "title": "Discussion"
        },
        {
            "endOffset": 31540,
            "parents": [],
            "secId": "s0005",
            "sentence": "We evaluated the immunogenicity and safety of 2 investigational 11- and 12-valent PHiD-CV vaccines that include capsular polysaccharides of serotypes 19A (11vPHiD-CV) and 6A and 19A (12vPHiD-CV) conjugated to CRM197.",
            "startOffset": 31324,
            "title": "Introduction"
        },
        {
            "endOffset": 37517,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A total of 940 infants (235 per group) were to be enrolled.",
            "startOffset": 37458,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38585,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Non-inferiority of 11vPHiD-CV was demonstrated if the upper limit (UL) of the 2-sided 95.9% CI (1-sided \u03b1 = 2.05%) of the difference in percentages of infants with pneumococcal antibody concentrations \u22650.2 \u00b5g/mL between comparator and investigational groups was lower than 10%, and if the UL of GMC ratios (comparator/investigational group) was below a limit of 2 for at least 9 out of 11 vaccine pneumococcal serotypes.",
            "startOffset": 38165,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43989,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month post-booster vaccination, for each PHiD-CV serotype and serotype 19A, the percentages of toddlers with antibody concentrations \u22650.2 \u00b5g/mL in both investigational groups increased to at least 98.1% (Table 1).",
            "startOffset": 43772,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 33436,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "To comply with the national immunisation schedule, all Spanish children also received a licensed meningococcal serogroup C-tetanus toxoid conjugate vaccine, administered concomitantly with the study vaccine at approximately 2, 4 and 12\u201315 months of age.",
            "startOffset": 33183,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53661,
            "parents": [],
            "secId": "s0070",
            "sentence": "OPA was only evaluated in a subset of participants; therefore, these results should be interpreted with caution.",
            "startOffset": 53549,
            "title": "Discussion"
        },
        {
            "endOffset": 44989,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "These percentages increased post-booster vaccination to at least 93.9%.",
            "startOffset": 44918,
            "title": "Immune response to pneumococcal serotypes and protein D"
        },
        {
            "endOffset": 37708,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming 85% of enrolled participants would be evaluable, power of the study to demonstrate non-inferiority was 97% for the first confirmatory objective and 90% for the second one (Text S3).",
            "startOffset": 37518,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 50618,
            "parents": [],
            "secId": "s0070",
            "sentence": "Eight months after completion of the primary series, antibody concentrations were similar among the 3 PHiD-CV groups for each of the 10 common pneumococcal serotypes.",
            "startOffset": 50452,
            "title": "Discussion"
        },
        {
            "endOffset": 36562,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Anti-protein D antibodies were quantified by an in-house ELISA with a cut-off of 100 ELISA Units (EL.U)/mL.",
            "startOffset": 36455,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 52908,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 52907,
                    "startOffset": 52903
                }
            },
            "secId": "s0070",
            "sentence": "AE incidence was comparable among groups receiving PHiD-CV formulations and corresponded to previously published results [38].",
            "startOffset": 52782,
            "title": "Discussion"
        },
        {
            "endOffset": 32647,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy infants 6\u201312 weeks of age who had not been previously vaccinated against S. pneumoniae and did not meet any of the exclusion criteria (Supplementary Material, Text S1) were enrolled in the study, after written informed consent was obtained from parents or legally acceptable representatives.",
            "startOffset": 32348,
            "title": "Study design and participants"
        },
        {
            "endOffset": 48305,
            "parents": [],
            "secId": "s0070",
            "sentence": "In our study, for serotype 19A, the non-inferiority criterion was met in terms of the percentage of infants with antibody concentration \u22650.2 \u03bcg/mL, but not in terms of antibody GMC ratios.",
            "startOffset": 48117,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X18309897",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "alfonsocarmona@ihppediatria.com",
                "first": "Alfonso",
                "initial": "A.",
                "last": "Carmona Martinez"
            },
            {
                "email": "prymula@fnhk.cz",
                "first": "Roman",
                "initial": "R.",
                "last": "Prymula"
            },
            {
                "email": "mariano.miranda@andaluciajunta.es",
                "first": "Mariano",
                "initial": "M.",
                "last": "Miranda Valdivieso"
            },
            {
                "email": "otero_car@gva.es",
                "first": "Maria del Carmen",
                "initial": "M.d.C.",
                "last": "Otero Reigada"
            },
            {
                "email": null,
                "first": "Jose Manuel",
                "initial": "J.M.",
                "last": "Merino Arribas"
            },
            {
                "email": "jerzy_br@poczta.onet.pl",
                "first": "Jerzy",
                "initial": "J.",
                "last": "Brzostek"
            },
            {
                "email": "leszek.szenborn@umed.wroc.pl",
                "first": "Leszek",
                "initial": "L.",
                "last": "Szenborn"
            },
            {
                "email": "drruzkova@email.cz",
                "first": "Renata",
                "initial": "R.",
                "last": "Ruzkova"
            },
            {
                "email": "info@drhorn.de",
                "first": "Michael R.",
                "initial": "M.R.",
                "last": "Horn"
            },
            {
                "email": "tjackowska@cmkp.edu.pl",
                "first": "Teresa",
                "initial": "T.",
                "last": "Jackowska"
            },
            {
                "email": "fcentenoma@saludcastillayleon.es",
                "first": "Fernando",
                "initial": "F.",
                "last": "Centeno-Malfaz"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": null,
                "first": "Kurt",
                "initial": "K.",
                "last": "Dobbelaere"
            },
            {
                "email": "dorota.d.borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.07.023",
        "firstpage": "176",
        "issn": "0264410X",
        "keywords": [
            "Immunogenicity",
            "Infants/children",
            "Non-inferiority",
            "PHiD-CV",
            "Pneumococcal conjugate vaccine",
            "Safety"
        ],
        "lastpage": "186",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study"
    }
}